Compare Amgen, Inc. (AMGN) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs MobilEye Global Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while MobilEye Global Inc trades at $9.48 (market cap $8.04B). The key difference: Amgen, Inc. is far larger — about 24.4× MobilEye Global Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals.
| AMGN | MBLY | |
|---|---|---|
Market Cap | $196.12B | $8.04B |
Sector | Health | Technology |
52-Week High | $388.16 | $16.57 |
52-Week Low | $271.18 | $6.56 |
Enterprise Value | $241.41B | $6.70B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Mobileye (MBLY) trades at $9.55, up 0.21% with a bullish technical signal. The company shows strong revenue growth ($1.89B in 2025) but significant net losses (-$392M). Recent earnings beat expectations in Q1 2026, while analysts maintain a 57.69% buy rating with a $10.36 consensus target. The stock faces pressure from negative profitability metrics but benefits from positive sentiment around its 2027 robotaxi launch plans.
MBLY presents a high-risk opportunity with transformative potential through autonomous driving technology. The upcoming robotaxi business could drive long-term growth, but current financial losses and competitive pressures require careful monitoring. Investor sentiment remains cautiously optimistic pending execution of strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
